The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.
Koichi Azuma
No relevant relationships to disclose
Hiroshige Yoshioka
Honoraria - Chugai Pharma
Nobuyuki Yamamoto
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Chugai Pharma
Toshiaki Takahashi
No relevant relationships to disclose
Makoto Nishio
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Pfizer; Taiho Pharmaceutical
Nobuyuki Katakami
Honoraria - Chugai Pharma
Myung-Ju Ahn
No relevant relationships to disclose
Tomonori Hirashima
No relevant relationships to disclose
Makoto Maemondo
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma
Research Funding - Boehringer Ingelheim
Sang-We Kim
No relevant relationships to disclose
Masayoshi Noshiro
Employment or Leadership Position - Kyowa Hakko Kirin
Shiro Akinaga
Employment or Leadership Position - Kyowa Hakko Kirin
Keunchil Park
Consultant or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Clovis; Lilly; Roche
Research Funding - AstraZeneca
Chun-Ming Tsai
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Pfizer; Roche
Tomohide Tamura
Honoraria - Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Pfizer
Tetsuya Mitsudomi
Consultant or Advisory Role - Chugai Pharma; Kyowa Hakko Kirin; Roche
Kazuhiko Nakagawa
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma